
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. is making significant strides in developing innovative immunotherapies, evidenced by its favorable safety profile in early studies of WTX-330 and promising preclinical results from its INDUKINE programs, WTX-712 and WTX-518, which demonstrated monotherapy anti-tumor activity. The company's proprietary PREDATOR platform not only enhances the safety and dosing flexibility of existing therapies but also shows potential for expanding applications in immune-mediated diseases beyond oncology. With notable clinical achievements from its WTX-124 asset, which has exhibited improved tolerability and a superior safety profile compared to traditional IL-2 therapies, Werewolf Therapeutics is positioned for substantial growth, supporting a positive financial outlook.
Bears say
Werewolf Therapeutics Inc. reported a significant net loss of $20.4 million, or ($0.46) per share, for the fourth quarter of 2024, marking an increase in losses compared to $12.0 million in the same quarter of the previous year. Concerns regarding the future success of the WTX-124 program persist, particularly related to potential clinical or regulatory setbacks, along with doubts about its differentiated safety, efficacy, and pharmacokinetic properties, which could hinder its commercial viability. Additionally, the company's expansion opportunities appear to be undervalued in the broader context of its financial outlook, suggesting that investor sentiment may remain cautious amid these challenges.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares